Anzeige
Mehr »
Login
Samstag, 13.07.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
Startschuss gefallen: Diese Aktie lässt die Konkurrenz alt aussehen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2AJ68 | ISIN: NL0011832936 | Ticker-Symbol: C43
Tradegate
11.07.24
10:31 Uhr
71,50 Euro
-2,00
-2,72 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
COSMO PHARMACEUTICALS NV Chart 1 Jahr
5-Tage-Chart
COSMO PHARMACEUTICALS NV 5-Tage-Chart
RealtimeGeldBriefZeit
72,5074,0012.07.
73,0074,0012.07.

Aktuelle News zur COSMO PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiRedHill terminates license agreement with Cosmo Technologies4
DiCosmo Pharmaceuticals N.V.: Invitation to Cosmo's Half-Year 2024 Webcast on 24 July 2024230Dublin, Ireland--(Newsfile Corp. - July 9, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) ("Cosmo") announced today that it will publish its Half-Year 2024 results on Wednesday, 24...
► Artikel lesen
05.07.Cosmo Pharmaceuticals N.V.: Cosmo Shareholders Approved All Resolutions Proposed by the Board of Directors at Extraordinary General Meeting639Shareholders approved a dividend distribution of € 2.00 per ordinary share; representing an increase of 90% versus last year Shareholders approved all other proposals of the Board...
► Artikel lesen
18.06.Cosmo Pharmaceuticals N.V.: Cosmo's Oral Diagnostic Drug Lumeblue(R) Receives Approval of New Drug Application in China291Dublin, Ireland--(Newsfile Corp. - June 18, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) ("Cosmo") reported that its partner and exclusive licensee of Lumeblue® (Methylene Blue MMX®)...
► Artikel lesen
05.06.Cosmo Pharmaceuticals N.V. reports FY results10
03.06.Cosmo Pharmaceuticals to declare EUR 2.00 dividend8
03.06.Cosmo Pharmaceuticals N.V.: Cosmo to Bring Real-Time AI into Intelligent Medical Devices with NVIDIA IGX320Dublin, Ireland--(Newsfile Corp. - June 3, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) ("Cosmo") with its Cosmo Intelligent Medical Devices division ("Cosmo IMD") is consolidating...
► Artikel lesen
01.06.Cosmo Pharmaceuticals N.V.: Cosmo Reports Excellent Final Full Year 2023 Financial Results - Increases Operating Profit Guidance for 2024 - Dividend of 2.00 per Share Will Be Proposed at EGM on 5 July 2024831Ad hoc announcement pursuant to Art. 53 LR Dublin, Ireland--(Newsfile Corp. - May 31, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) ("Cosmo") today announced its final audited results...
► Artikel lesen
24.05.Cosmo Pharmaceuticals N.V.: Cosmo Pharmaceuticals' Shareholders Approve All Agenda Items at Annual General Meeting862Dublin, Ireland--(Newsfile Corp. - May 24, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) ("Cosmo") today announced that its shareholders approved all agenda items at today's annual ...
► Artikel lesen
29.04.Cosmo Pharmaceuticals N.V.: Cosmo Has Received Approval of an Extension in Respect of the Publication and the Filing of Its Annual Report 2023486Ad hoc announcement pursuant to Art. 53 LR Dublin, Ireland--(Newsfile Corp. - April 29, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) ("Cosmo") today announced that the company...
► Artikel lesen
25.04.Cosmo Pharmaceuticals N.V.: Cosmo Announces Leadership Changes326Ad hoc announcement pursuant to Art. 53 LR Giovanni Di Napoli appointed as new CEO effective from 24 May 2024. Current CEO Alessandro Della Chà to be appointed as new Chairman...
► Artikel lesen
12.04.Cosmo Pharmaceuticals N.V.: Cosmo and Medtronic Unveil the Future of AI in GI: Genius Summit 2024 Reveals Innovations and Collaborations That Advance Endoscopic Care702Dublin, Ireland--(Newsfile Corp. - April 12, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) ("Cosmo") announces that Medtronic plc (NYSE: MDT), a global leader in healthcare technology...
► Artikel lesen
20.03.Cosmo Pharmaceuticals N.V.: Cosmo Reports Excellent Preliminary Unaudited Full Year 2023 Core Financial Results - Record Guidance for 2024 - Doubles Dividend to 2.00 per Share523Ad hoc announcement pursuant to Art. 53 LR Medtronic deal accounted in 2024, to inject USD 200m cash. FDA approval of GI Genius new enhanced operating system. New GI drug development...
► Artikel lesen
19.03.Cosmo Pharmaceuticals N.V.: Cosmo Pharmaceuticals Announces Approval of Winlevi(R) in Australia300Dublin, Ireland--(Newsfile Corp. - March 19, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) ("Cosmo") reported today that its partner Sun Pharmaceutical Industries Limited (Reuters:...
► Artikel lesen
19.02.CB-0311 by Cosmo Pharmaceuticals for Androgenic Alopecia: Likelihood of Approval24
25.01.Cosmo Pharmaceuticals N.V.: Invitation to Cosmo's Investor Day and Full-Year 2023 Webcast - Zurich, 20 March 2024403Dublin, Ireland--(Newsfile Corp. - January 25, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) ("Cosmo") announced today that it will publish its Full-Year 2023 results on Wednesday...
► Artikel lesen
11.12.23Medtronic And Cosmo Pharma's Expanded Partnership To Incorporate AI Into Endoscopic Care670FRIDLEY (dpa-AFX) - Medtronic plc (MDT), a healthcare technology company, Monday announced that it agreed with Cosmo Intelligent Medical Devices, a unit of Cosmo Pharmaceuticals to expand partnership...
► Artikel lesen
11.12.23Cosmo Pharmaceuticals N.V.: Cosmo Pharmaceuticals and Medtronic Forge Ahead in AI-Driven Care390Agreement Expands Partnership Between Cosmo Pharmaceuticals and Medtronic, Set to Transform Endoscopy with Cutting-Edge AI Technology Ad hoc announcement pursuant to Art. 53 LR Dublin,...
► Artikel lesen
06.12.23Cosmo Pharmaceuticals N.V.: Cosmo bestätigt vollständige Rückzahlung in bar von EUR 175 Mio. Wandelanleihen497Cosmo Pharmaceuticals N.V. / Schlagwort(e): Anleihe Cosmo bestätigt vollständige Rückzahlung in bar von EUR 175 Mio. Wandelanleihen 06.12.2023 / 06:00 GMT/BST Dublin,...
► Artikel lesen
10.10.23Cosmo Pharmaceuticals N.V.: Cosmo reicht Zulassungsantrag für Winlevi® bei der Europäischen Arzneimittel-Agentur (EMA) ein623Cosmo Pharmaceuticals N.V. / Schlagwort(e): Zulassungsantrag Cosmo reicht Zulassungsantrag für Winlevi® bei der Europäischen Arzneimittel-Agentur (EMA) ein 10.10.2023...
► Artikel lesen
Seite:  Weiter >>
28 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,3